Which medicines are covered The PAP only covers a specific list of Novo Nordisk registered trademark medicines, which currently includes certain GLP-1 medications (Ozempic, Rybelsus and Xultophy), insulin products (Fiasp, Novolin R, Novolin N and Novolin 70/30, NovoLog Vial, NovoLog PenFill and Flexpen, NovoLog Mix, Tresiba), devices (Novopen, NovoFine), and other selected specialty therapies
Summary: Mounjaro (tirzepatide) is not specifically contraindicated in Crohn's disease, but requires careful individualised assessment due to overlapping gastrointestinal side effects and limited evidence in inflammatory bowel disease populations
Others can be influenced but only to a point
Unlike Zepbound, Mounjaros primary approval is for type 2 diabetes management, not specifically for weight loss
Eating a small, balanced snack containing complex carbohydrates and protein before bed may help stabilise blood glucose levels overnight
Poor diet and insufficient hydration can also increase the risk